Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
CSPC Pharmaceutical Group ( (HK:1093) ) has shared an update.
CSPC Pharmaceutical Group announced that its subsidiary has obtained marketing approval from China’s National Medical Products Administration for a new indication of Enyitan, an omalizumab biosimilar. This approval marks the second indication for Enyitan in China, enhancing CSPC’s product portfolio and strengthening its position in the biosimilar market.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a leading company in the pharmaceutical industry, focusing on the development of therapeutic biological products. It offers a range of products, including biosimilar drugs, with a market focus on China.
YTD Price Performance: -1.19%
Average Trading Volume: 8,854
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.73B
For a thorough assessment of 1093 stock, go to TipRanks’ Stock Analysis page.
